| 2026-10-01in 37 d | Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity | AMGNAmgen | Phase 1 | Cardiometabolic Disease | Recruiting |
| 2026-10-01in 37 d | A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs | AZNAstraZeneca | — | Pancreatic Cancer | Recruiting |
| 2026-10-01in 37 d | A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan | BMYBristol-Myers Squibb | — | β-Thalassemia Major | Active, not recruiting |
| 2026-10-01in 37 d | Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice | BMYBristol-Myers Squibb | — | Esophageal Cancer | Active, not recruiting |
| 2026-10-01in 37 d | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus | COCPCocrystal Pharma, Inc. | Phase 1/2 | Norovirus | Recruiting |
| 2026-10-01in 37 d | The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) | NTRANatera, Inc. | — | Kidney Transplant Rejection | Active, not recruiting |
| 2026-10-01in 37 d | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | NVONovo Nordisk A/S | Phase 3 | Heart Failure | Active, not recruiting |
| 2026-10-01in 37 d | Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy | PFEPfizer | — | Respiratory Syncytial Virus | Active, not recruiting |
| 2026-10-02in 38 d | AZD5305 hADME in Patients With Advanced Solid Malignancies | AZNAstraZeneca | Phase 1 | Locally Advanced or Metastatic Solid Tumor | Recruiting |
| 2026-10-02in 38 d | Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | PSTVPlus Therapeutics | Phase 1 | Leptomeningeal Metastasis | Recruiting |
| 2026-10-05in 41 d | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | MRNAModernaTX, Inc. | Phase 1/2 | Epstein-Barr Virus Infection | Active, not recruiting |
| 2026-10-05in 41 d | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | SOBI.STSwedish Orphan Biovitrum | Phase 3 | Myelofibrosis | Active, not recruiting |
| 2026-10-06in 42 d | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | BMYBristol-Myers Squibb | Phase 3 | Idiopathic Pulmonary Fibrosis | Active, not recruiting |
| 2026-10-07in 43 d | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | REGNRegeneron Pharmaceuticals | Phase 3 | Atopic Dermatitis | Active, not recruiting |
| 2026-10-08in 44 d | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | AMGNAmgen | Phase 1 | Prostate Cancer | Active, not recruiting |
| 2026-10-08in 44 d | A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population | AZNAstraZeneca | — | Asthma | Recruiting |
| 2026-10-09in 45 d | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | INCYIncyte Corporation | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-10-09in 45 d | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | INCYIncyte Corporation | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-10-09in 45 d | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | PFEPfizer | Phase 1 | Pancreatic Cancer | Active, not recruiting |
| 2026-10-12in 48 d | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | BMYBristol-Myers Squibb | Phase 1/2 | Multiple Myeloma | Recruiting |
| 2026-10-12in 48 d | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | REGNRegeneron Pharmaceuticals | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | Active, not recruiting |
| 2026-10-13in 49 d | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | MRNAModernaTX, Inc. | Phase 1 | Epstein-Barr Virus Infection | Active, not recruiting |
| 2026-10-14in 50 d | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | SNYSanofi | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2026-10-15in 51 d | Retention Rate of Acalabrutinib in a Non-interventional Setting | AZNAstraZeneca | — | Chronic Lymphocytic Leukaemia (CLL) | Active, not recruiting |
| 2026-10-15in 51 d | A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) | AZNAstraZeneca | Phase 1/2 | RSV Respiratory Syncytial Virus | Recruiting |
| 2026-10-15in 51 d | Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | SLDBSolid Biosciences Inc. | Phase 1/2 | Duchenne Muscular Dystrophy | Active, not recruiting |
| 2026-10-19in 55 d | Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics | AZNAstraZeneca | Phase 4 | Asthma | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | BMYBristol-Myers Squibb | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | BMYBristol-Myers Squibb | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | INCYIncyte Corporation | Phase 3 | Prurigo Nodularis | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | INCYIncyte Corporation | Phase 3 | Prurigo Nodularis | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants | INCYIncyte Corporation | Phase 1 | Healthy Participants | Recruiting |
| 2026-10-19in 55 d | A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis | PFEPfizer | Phase 2 | Atopic Dermatitis | Recruiting |
| 2026-10-19in 55 d | Tempus Priority Study: A Pan-tumor Observational Study | TEMTempus AI | — | Breast Cancer | Active, not recruiting |
| 2026-10-20in 56 d | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | 4568.TDaiichi Sankyo | Phase 1/2 | Solid Tumors | Recruiting |
| 2026-10-20in 56 d | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | BIIBBiogen | Phase 2/3 | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Active, not recruiting |
| 2026-10-21in 57 d | A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants | AZNAstraZeneca | Phase 1 | Healthy Participants | Recruiting |
| 2026-10-22in 58 d | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State | AMGNAmgen | Phase 3 | Sjögren's Syndrome (SS) | Active, not recruiting |
| 2026-10-23in 59 d | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | AZNAstraZeneca | Phase 2 | Lung Cancer | Active, not recruiting |
| 2026-10-26in 62 d | Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany | NVONovo Nordisk A/S | — | Hemophilia A | Not yet recruiting |
| 2026-10-27in 63 d | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | AZNAstraZeneca | Phase 2 | Hepatocellular Carcinoma | Active, not recruiting |
| 2026-10-28in 64 d | The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management | AZNAstraZeneca | Not applicable | Cardiovascular Diseases | Recruiting |
| 2026-10-28in 64 d | A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD) | SNYSanofi | — | Glycogen Storage Disease Type II | Active, not recruiting |
| 2026-10-29in 65 d | Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants | AZNAstraZeneca | Phase 1 | Healthy | Recruiting |
| 2026-10-30in 66 d | Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease | AZNAstraZeneca | Phase 4 | COPD | Recruiting |
| 2026-10-30in 66 d | Evaluating the Pharmacokinetics and Safety of Miricorilant | CORTCorcept Therapeutics | Phase 1 | MASH / Nonalcoholic Steatohepatitis | Recruiting |
| 2026-10-30in 66 d | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity | MBXMBX Biosciences | Phase 1 | Obesity | Recruiting |
| 2026-10-30in 66 d | Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | NVONovo Nordisk A/S | — | Type 2 Diabetes | Not yet recruiting |
| 2026-10-30in 66 d | A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in Adults | NYXH.BRNyxoah S.A. | Not applicable | Obstructive Sleep Apnea | Active, not recruiting |
| 2026-10-30in 66 d | A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older | PFEPfizer | — | Community-Acquired Pneumonia (CAP) | Active, not recruiting |
| 2026-10-30in 66 d | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Cystic Fibrosis | Active, not recruiting |
| 2026-10-31in 67 d | Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment | 4568.TDaiichi Sankyo | Phase 1 | Hepatic Impairment | Recruiting |
| Oct 2026≤ 67 d | A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis | ABBVAbbVie | — | Atopic Dermatitis | Active, not recruiting |
| Oct 2026≤ 67 d | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | ABBVAbbVie | Phase 3 | Age-Related Macular Degeneration | Active, not recruiting |
| Oct 2026≤ 67 d | Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Recruiting |
| Oct 2026≤ 67 d | A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants | ABBVAbbVie | Phase 2 | Forehead Lines | Recruiting |
| Oct 2026≤ 67 d | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) | ABOSAcumen Pharmaceuticals | Phase 2 | Alzheimer's Disease | Active, not recruiting |
| 2026-10-31in 67 d | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | ADAGAdagene Inc | Phase 1/2 | Solid Tumors | Recruiting |
| Oct 2026≤ 67 d | SAD and MAD Study of AKB-9090 in Healthy Adult Participants | AKBAAkebia Therapeutics | Phase 1 | Healthy Volunteers | Recruiting |
| 2026-10-31in 67 d | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | AMGNAmgen | Phase 1 | Lung Cancer | Active, not recruiting |
| 2026-10-31in 67 d | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | AMGNAmgen | Phase 1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | Active, not recruiting |
| 2026-10-31in 67 d | A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | AMGNAmgen | Phase 2 | MTAP-deleted NSCLC | Active, not recruiting |
| 2026-10-31in 67 d | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | ANNXAnnexon, Inc. | Phase 3 | Geographic Atrophy | Active, not recruiting |
| 2026-10-31in 67 d | Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation) | AZNAstraZeneca | — | Life Threatening Bleeding, Factor Xa Inhibitor | Recruiting |
| 2026-10-31in 67 d | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients | AZNAstraZeneca | Phase 4 | Breast Cancer | Recruiting |
| 2026-10-31in 67 d | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients | AZNAstraZeneca | Phase 3 | Breast Cancer | Active, not recruiting |
| Oct 2026≤ 67 d | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | BCRXBioCryst Pharmaceuticals | Phase 1 | Netherton Syndrome | Recruiting |
| 2026-10-31in 67 d | A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) | BIIBBiogen | — | Multiple Sclerosis | Active, not recruiting |
| 2026-10-31in 67 d | A Rollover Study of CC-122 | BMYBristol-Myers Squibb | Phase 1 | Non-Hodgkin Lymphoma | Active, not recruiting |
| 2026-10-31in 67 d | Asia Myelodysplastic Syndrome (MDS) Registry | BMYBristol-Myers Squibb | — | Myelodysplastic Syndromes | Not yet recruiting |
| Oct 2026≤ 67 d | A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions | BNTXBioNTech SE | Phase 1 | Genital Herpes Simplex Type 2 | Active, not recruiting |
| 2026-10-31in 67 d | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | BSXBoston Scientific Corporation | Phase 1 | Glioblastoma | Recruiting |
| 2026-10-31in 67 d | cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia | BSXBoston Scientific Corporation | — | Atrial Fibrillation | Recruiting |
| Oct 2026≤ 67 d | Ceribell Delirium Monitor Outcomes Pilot Study | CBLLCeribell Inc. | Not applicable | Delirium in the Intensive Care Unit | Recruiting |
| Oct 2026≤ 67 d | Clinical Study to Evaluate Remineralization Using an in Situ Model. | CLColgate Palmolive | Phase 3 | Remineralization, Enamel Lesions, Enamel Subsurface Lesion | Not yet recruiting |
| Oct 2026≤ 67 d | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | CLDXCelldex Therapeutics | Phase 3 | Chronic Spontaneous Urticaria | Active, not recruiting |
| Oct 2026≤ 67 d | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | CLDXCelldex Therapeutics | Phase 3 | Chronic Spontaneous Urticaria | Active, not recruiting |
| Oct 2026≤ 67 d | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | CORTCorcept Therapeutics | Phase 2 | Amyotrophic Lateral Sclerosis | Recruiting |
| Oct 2026≤ 67 d | A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome | CRNXCrinetics Pharmaceuticals Inc. | Phase 1/2 | Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome | Active, not recruiting |
| Oct 2026≤ 67 d | Portrait Mobile Monitoring Solution V2.0 External Evaluation | GEHCGE Healthcare | Not applicable | Monitoring | Not yet recruiting |
| 2026-10-31in 67 d | NMT EasyFit Sensor and Cable | GEHCGE Healthcare | Not applicable | Neuromuscular Blockade Monitoring, NMT | Recruiting |
| Oct 2026≤ 67 d | Study of Sacituzumab Govitecan in Patients With Solid Tumor | GILDGilead Sciences | Phase 2 | Solid Tumors | Active, not recruiting |
| Oct 2026≤ 67 d | Study of GS-4528 in Adults With Solid Tumors | GILDGilead Sciences | Phase 1 | Solid Tumors | Active, not recruiting |
| Oct 2026≤ 67 d | A Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health | HLNHALEON | Not applicable | Gingivitis | Recruiting |
| Oct 2026≤ 67 d | A Comprehensive Digital Care Program for Migraine Management | HNGEHinge Health, Inc | Not applicable | Migraine | Recruiting |
| Oct 2026≤ 67 d | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan) | IBAB.BRIon Beam Applications | Not applicable | Solid Tumors | Active, not recruiting |
| Oct 2026≤ 67 d | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen) | IBAB.BRIon Beam Applications | Not applicable | Solid Tumors | Active, not recruiting |
| Oct 2026≤ 67 d | A Study to Assess Anktiva in Patients With Long Covid-19. | IBRXImmunityBio, Inc. | Phase 2 | Long COVID | Recruiting |
| Oct 2026≤ 67 d | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | IDYAIDEAYA Biosciences | Phase 1 | Solid Tumors | Active, not recruiting |
| Oct 2026≤ 67 d | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | IMCRImmunocore Ltd | Phase 1/2 | Solid Tumors | Active, not recruiting |
| Oct 2026≤ 67 d | Study of DISC-0974-201 in Participants With IBD and Anemia | IRONDisc Medicine, Inc | Phase 2 | Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia | Recruiting |
| Oct 2026≤ 67 d | Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. | JANXJanux Therapeutics | Early Phase 1 | Autoimmune | Recruiting |
| Oct 2026≤ 67 d | A Phase 1 Study of JADE101 in Healthy Participants | JBIOJade Biosciences, Inc. | Phase 1 | Healthy Volunteers | Active, not recruiting |
| Oct 2026≤ 67 d | A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) | LLYEli Lilly and Company | Phase 3 | Systemic Juvenile Idiopathic Arthritis | Active, not recruiting |
| Oct 2026≤ 67 d | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | LLYEli Lilly and Company | Phase 3 | Type 2 Diabetes | Active, not recruiting |
| Oct 2026≤ 67 d | A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function | LLYEli Lilly and Company | Phase 1 | Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease | Active, not recruiting |
| Oct 2026≤ 67 d | A Study of Eloralintide (LY3841136) in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy Volunteers | Recruiting |
| Oct 2026≤ 67 d | A Study of LY4268989 (MORF 057) in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Recruiting |
| Oct 2026≤ 67 d | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | MIRMMirum Pharmaceuticals, Inc. | Phase 3 | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Active, not recruiting |
| Oct 2026≤ 67 d | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | NTHINeonc Technologies, Inc. | Phase 1 | Glioma | Not yet recruiting |
| 2026-10-31in 67 d | Prospera Test Evaluation in Cardiac Transplant (ProTECT) | NTRANatera, Inc. | — | Heart Transplant Rejection | Active, not recruiting |
| Oct 2026≤ 67 d | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | OGNOrganon and Co | Phase 3 | Psoriasis | Active, not recruiting |
| 2026-10-31in 67 d | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | OLMAOlema Pharmaceuticals, Inc. | Phase 3 | Breast Cancer | Active, not recruiting |
| Oct 2026≤ 67 d | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks | PHATPhathom Pharmaceuticals, Inc. | Phase 2 | Eosinophilic Esophagitis | Active, not recruiting |
| Oct 2026≤ 67 d | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma | PHIL.MIPhilogen S.p.A. | Phase 1/2 | Glioblastoma | Recruiting |
| Oct 2026≤ 67 d | NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System | PLSEPulse Biosciences, Inc. | Not applicable | Atrial Fibrillation | Recruiting |
| 2026-10-31in 67 d | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | REPLReplimune, Inc. | Phase 1 | Cancer | Active, not recruiting |
| 2026-10-31in 67 d | Registry Study on Prescription, Patient Pathways, Therapy Efficacy and Usage of Mandibular Advancement Devices in Obstructive Sleep Apnea - PATT-OSA Registry | RMDResMed | — | Obstructive Sleep Apnea | Active, not recruiting |
| Oct 2026≤ 67 d | Circadian Rhythm Monitoring Study | RMDResMed | Not applicable | Circadian Rhythm | Not yet recruiting |
| Oct 2026≤ 67 d | Exploration of Current and New Technologies for Accuracy of Diagnosing OSA | RMDResMed | — | Obstructive Sleep Apnea | Not yet recruiting |
| 2026-10-31in 67 d | A Study of Setmelanotide in Patients With Prader-Willi Syndrome | RYTMRhythm Pharmaceuticals, Inc. | Phase 2 | Obesity | Active, not recruiting |
| 2026-10-31in 67 d | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | SRPTSarepta Therapeutics, Inc. | Phase 3 | Duchenne Muscular Dystrophy | Active, not recruiting |
| 2026-10-31in 67 d | A Study of SPY072 in Rheumatic Disease | SYRESpyre Therapeutics, Inc. | Phase 2 | Rheumatoid Arthritis | Active, not recruiting |
| 2026-10-31in 67 d | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk | TGTXTG Therapeutics, Inc. | — | Multiple Sclerosis | Recruiting |
| 2026-10-31in 67 d | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | TGTXTG Therapeutics, Inc. | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| Oct 2026≤ 67 d | OCS DCD Heart + CAP Continued Follow-Up | TMDXTransMedics | — | Heart Transplant | Active, not recruiting |
| Oct 2026≤ 67 d | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | VNDAVanda Pharmaceuticals | Phase 2 | Hypertension | Recruiting |
| Oct 2026≤ 67 d | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | XENEXenon Pharmaceuticals Inc. | Phase 3 | Epilepsy and Seizure Disorders | Recruiting |
| Oct 2026≤ 67 d | Hi-Fatigue G Bone Cement Retrospective Study | ZBHZimmer Biomet | — | Total Hip and Knee Arthroplasties | Recruiting |
